

Biocept, Quest to provide liquid biopsy testing for lung cancer patients

September 2021—Biocept announced a collaboration with Quest Diagnostics to provide laboratory testing services to Quest patients for its Target Selector NGS-based liquid-biopsy-targeted lung cancer panel.

The Biocept Target Selector assay is a laboratory-developed test that can be used for genomic profiling in patients with advanced non-small cell lung cancer to help qualify them for advanced targeted therapies and monitor the effectiveness of treatment. With a physician order, patients will be able to provide a blood specimen for testing at one of Quest's 2,200 patient service centers in the United States. Biocept and Quest expect the service to be available in the fourth quarter of this year.

The panel includes the most prevalent clinically actionable genes for NSCLC, the company says. Approximately 70 percent of the biomarkers investigated are based on National Comprehensive Cancer Center guidelines and/or FDA-approved therapies.

In a separate statement, Biocept announced the launch of its CNSide cerebrospinal fluid assay, which detects cancer that has metastasized to the central nervous system. The company's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers.

[Biocept](#), 858-320-8200